Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm
Andrew J. Wiemer
ACS Pharmacology & Translational Science (2020) Vol. 3, Iss. 4, pp. 613-626
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

COVID-19: Characteristics and Therapeutics
Rameswari Chilamakuri, Saurabh Agarwal
Cells (2021) Vol. 10, Iss. 2, pp. 206-206
Open Access | Times Cited: 262
Modular and Facile Access to Chiral α-Aryl Phosphates via Dual Nickel- and Photoredox-Catalyzed Reductive Cross-Coupling
Hepan Wang, Purui Zheng, Xiaoqiang Wu, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 9, pp. 3989-3997
Closed Access | Times Cited: 71
The landscape of small-molecule prodrugs
Zachary Fralish, Ashley Chen, Shaharyar M. Khan, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 5, pp. 365-380
Closed Access | Times Cited: 30
Recent Advances in Synthesis of Difluoromethylene Phosphonates for Biological Applications
Michael Shevchuk, Qian Wang, Romana Pajkert, et al.
Advanced Synthesis & Catalysis (2021) Vol. 363, Iss. 12, pp. 2912-2968
Closed Access | Times Cited: 53
Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
Jiashu Xie, Zhengqiang Wang
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 6, pp. 1607-1616
Open Access | Times Cited: 49
Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2
Richard L. Mackman
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 3, pp. 338-347
Open Access | Times Cited: 32
A novel phosphocholine‐mimetic inhibits a pro‐inflammatory conformational change in C‐reactive protein
Johannes Zeller, Karen S. Cheung Tung Shing, Tracy L. Nero, et al.
EMBO Molecular Medicine (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 30
How to use COVID-19 antiviral drugs in patients with chronic kidney disease
Ajinath Kale, Vishwadeep Shelke, Neha Dagar, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 22
Enantioconvergent Reductive C(sp)−C(sp3) Cross‐Coupling to Access Chiral α‐Alkynyl Phosphonates Under Dual Nickel/Photoredox Catalysis
Hepan Wang, Xiaoqiang Wu, Tao Xu
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 18
Closed Access | Times Cited: 18
Emerging procedures and solvents in biological sample pre-treatment
Valentina Greco, Alessandro Giuffrida, Marcello Locatelli, et al.
Advances in Sample Preparation (2023) Vol. 6, pp. 100066-100066
Open Access | Times Cited: 17
In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase
İsmail Çeli̇k, Meryem Erol, Zekeriya Düzgün
Molecular Diversity (2021) Vol. 26, Iss. 1, pp. 279-292
Open Access | Times Cited: 40
Over 40 Years of Fosmidomycin Drug Research: A Comprehensive Review and Future Opportunities
Talea Knak, Mona A. Abdullaziz, Stefan Höfmann, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1553-1553
Open Access | Times Cited: 22
Function and inhibition of the DNA repair enzyme SNM1A
Mark Berney, Steven Ferguson, Joanna F. McGouran
Bioorganic Chemistry (2025), pp. 108225-108225
Closed Access
Synthesis and Evaluation of Triazole-Containing Aryl/Acyloxy Prodrugs of a BTN3A1 Ligand
Umed Singh, Girija Pawge, Parker A Kintigh, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117345-117345
Closed Access
Impact of Remdesivir Treatment on Factor VIII Gene Expression and Hematological Parameters in COVID-19 Patients
Ghazal Kakavand, Somayeh Arabzadeh, Sohameh Mohebbi, et al.
Microbial Pathogenesis (2025), pp. 107536-107536
Closed Access
Optimization of a DNA encoded library derived autotaxin inhibitor hit to a potent in vivo LPA lowering quinazolinone compound with a non‑zinc binding mode
Rainer E. Martin, Alexander L. Satz, Christoph Kuratli, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130221-130221
Closed Access
Phosphate moiety in FDA‐approved pharmaceutical salts and prodrugs
Ameya Fulmali, Sonali S. Bharate
Drug Development Research (2022) Vol. 83, Iss. 5, pp. 1059-1074
Closed Access | Times Cited: 18
Prodrugs of pyrophosphates and bisphosphonates: disguising phosphorus oxyanions
Emma S. Rudge, Alex H. Y. Chan, Finian J. Leeper
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 4, pp. 375-391
Open Access | Times Cited: 17
Harnessing Oxetane and Azetidine Sulfonyl Fluorides for Opportunities in Drug Discovery
Oliver L. Symes, Hikaru Ishikura, Callum S. Begg, et al.
Journal of the American Chemical Society (2024)
Open Access | Times Cited: 3
Novel Prodrug Strategies for the Treatment of Tuberculosis
Christine Kim, Jiney Jose, Michael P. Hay, et al.
Chemistry - An Asian Journal (2024) Vol. 19, Iss. 23
Open Access | Times Cited: 2
Prodrugs: General concepts and prodrug design in medicinal chemistry
Damiano Tanini, Andrea Angeli, Claudiu T. Supuran
Elsevier eBooks (2024), pp. 3-19
Closed Access | Times Cited: 2
Prodrugging fungicidal Amphotericin B significantly decreases its toxic effects
Ondřej Štěpánek, Marie Parigger, Eliška Procházková, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117157-117157
Closed Access | Times Cited: 2
Synthesis of chiral allylic phosphonates via asymmetric reductive cross-coupling of α-bromophosphonates and vinyl bromides
Hepan Wang, Xinxuan Li, Tao Xu
Science China Chemistry (2023) Vol. 66, Iss. 9, pp. 2621-2625
Closed Access | Times Cited: 6
Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection
Jiapeng Li, Shuhan Liu, Jian Shi, et al.
Pharmaceutics (2021) Vol. 13, Iss. 10, pp. 1656-1656
Open Access | Times Cited: 14
Expanding the toolbox of metabolically stable lipid prodrug strategies
Kiran S. Toti, Nicole Pribut, Michael P. D’Erasmo, et al.
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top